Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
NEJM 349:2023-2033, Colao,A.,et al, 2003
Psychotic Reactions During Treatment of Pituitary Tumours with Dopamine Agonists
BMJ 289:1101-1103, Turner,T.H.,et al, 1984
Prolactinoma
NEJM 349:2035-2041, Schlechte,J.A., 2003
Management of Pituitary Tumors
Ann Int Med 129:472-483, Shimon,I.&Melmed,S., 1998
Complications of Transsphenoidal Surgery:Results of a National Survey, Review of the Literature, and Personal Experience
Neurosurg 40:225-236, Ciric,I.,et al, 1997
Arterial Injuries in Transsphenoidal Surgery for Pituitary Adenoma:The Role of Angiography and Endovascular Treatment
ANJR 18:655-665, Raymond,J.,et al, 1997
Octreotide
NEJM 334:246-254, Lamberts,S.W.J.,et al, 1996
Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993
Octreotide Treatment of Acromegaly, A Randomized, Multicenter Study
Ann Int Med 117:711-718, Ezzat,S.,et al, 1992
Diagnosis and Management of Hormone-Secreting Pituitary Adenomas
NEJM 324:822-831, Klibanski,A.&Zervas,N.T., 1991
Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide
Arch Int Med 151:1573-1578, Vance,M.L.&Harris,A.G., 1991
Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-Acting Non-Ergot Dopamine Agonist CV 205-502
Ann Int Med 112:668-673, Vance,M.L.,et al, 1990
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Effect of Dopamine Agonist Withdrawal After Long-Term Therapy in Prolactinomas
Lancet 2:187-192, Johnston,D.G.,et al, 1984
Reduction in Size of Prolactin-secreting Tumours in Men Treated with Pergolide
BMJ 285:465-467, Kendall-Taylor,P.,et al, 1982
The Prolactinoma Problem
NEJM 300:313-315, Reichlin,S., 1979